Published in Theor Biol Med Model on February 03, 2006
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology (2008) 1.68
Does the immune reaction cause malignant transformation by disrupting cell-to-cell or cell-to-matrix communications? Theor Biol Med Model (2007) 0.87
"First do no harm" and the importance of prediction in oncology. EPMA J (2010) 0.86
Immunostimulation and immunoinhibition of premalignant lesions. Theor Biol Med Model (2007) 0.85
Immunoediting: evidence of the multifaceted role of the immune system in self-metastatic tumor growth. Theor Biol Med Model (2012) 0.83
Therapeutic anti-tumor vaccines: from tumor inhibition to enhancement. Clin Med Oncol (2008) 0.82
The biological sense of cancer: a hypothesis. Theor Biol Med Model (2006) 0.81
The paradoxical effects of splenectomy on tumor growth. Theor Biol Med Model (2006) 0.78
Autoantibodies to mesothelin in infertility. Cancer Epidemiol Biomarkers Prev (2011) 0.78
Concern Oral sex, cancer and death: sexually transmitted cancers. Head Neck Oncol (2012) 0.76
Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1957) 10.10
The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 9.39
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res (1960) 5.31
The origin and function of tumor-associated macrophages. Immunol Today (1992) 5.12
A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer (1976) 4.76
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature (2005) 3.70
The immune reaction as a stimulator of tumor growth. Science (1972) 2.63
Immunodepression and malignancy. Adv Cancer Res (1975) 2.17
Cancer: inflammation by remote control. Nature (2005) 1.85
Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med (2003) 1.84
Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS (2005) 1.84
An immunostimulation theory of tumor development. Transplant Rev (1971) 1.72
Heterotransplantation of human cancers into nude mice: a model system for human cancer chemotherapy. Cancer (1978) 1.64
Maintenance of biological and biochemical characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer (1978) 1.53
Immunological surveillance in neoplasia. Transplant Rev (1971) 1.44
ANTIGENIC SPECIFICITY OF BENZO(A)PYRENE-INDUCED SARCOMAS. J Natl Cancer Inst (1964) 1.34
A unifying concept of the etiology of the leukemias, lymphomas, and cancers. J Natl Cancer Inst (1957) 1.25
Relationship of tumor immunogenicity to concentration of the oncogen. J Natl Cancer Inst (1975) 1.20
Stimulatory effects of immune reactions upon the growths of untransplanted tumors. Cancer Res (1994) 1.19
Perspectives on oncogenesis: does immunity stimulate or inhibit neoplasia? J Reticuloendothel Soc (1971) 1.14
Tumors of the immunocompromised patient. Annu Rev Med (1988) 1.08
Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer (1991) 1.06
Reduced incidence of rectal cancer, compared to gastric and colonic cancer, in a population of 73,076 men and women chronically immunosuppressed. Clin Cancer Res (1997) 1.02
Immune status of the primary host toward its own methylcholanthrene-induced sarcomas. J Natl Cancer Inst (1968) 1.00
MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol (1997) 0.98
Analysis of antigenic heterogeneity within individual 3-methylcholanthrene-induced mouse sarcomas. J Natl Cancer Inst (1970) 0.97
Development of carcinogen-induced skin tumors in mice with varied states of immune capacity. Int J Cancer (1980) 0.96
Surveillance, latency and the two levels of MCA-induced tumor immunogenicity. Int J Cancer (1987) 0.93
The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice. Med Oncol (1999) 0.92
Immunostimulation of chemical oncogenesis in the mouse. Int J Cancer (1977) 0.89
Primary tumor immunity in nude mice. Int J Cancer (1977) 0.88
Effect of host immunity on the antigenic strength of primary tumors. J Natl Cancer Inst (1972) 0.88
EFFECT OF EARLY THYMECTOMY ON DEVELOPMENT OF MAMMARY TUMOURS IN MICE. Nature (1964) 0.88
Cytokines as positive and negative regulators of tumor promotion and progression. Semin Cancer Biol (1992) 0.86
Stimulation of tumor growth by the immune response. Int J Cancer (1974) 0.86
Immune status of autochthonous and adoptively protected mice toward spontaneous and chemically induced tumors. Cancer Res (1972) 0.85
Activation of ras oncogenes and expression of tumor-specific transplantation antigens in methylcholanthrene-induced murine fibrosarcomas. Int J Cancer (1991) 0.84
Effect of thymectomy on the induction of skin tumours by dibenzanthracene, and of breast tumours by dimethylbenzanthracene, in mice of the IF strain. Br J Cancer (1968) 0.84
Epidermal growth factor induces terminal differentiation in human epidermoid carcinoma cells. J Cell Physiol (1993) 0.83
Immunostimulation of highly immunogenic target tumor cells by lymphoid cells in vitro. J Natl Cancer Inst (1976) 0.83
Influence of immune status of host on immunogenicity of tumors induced with two doses of methylcholanthrene. Cancer Immunol Immunother (1982) 0.82
Paradoxical effect of three-day thymectomy on sarcogenesis in the mouse with different dosages of methylcholanthrene. Cancer Res (1986) 0.80
Autoantibody and tumor promotion. Proc Soc Exp Biol Med (1980) 0.80
Cancer vaccines 2004 opening address: the molecular and cellular basis of cancer immunosurveillance and immunoediting. Cancer Immun (2005) 0.80
Sarcoma induction in mice by methylcholanthrene. Antigenicity tests of sarcomas induced in thymus grafted and control animals. Br J Cancer (1969) 0.79
Stimulatory effect of immunization on tumor induction by Moloney murine sarcoma virus. J Natl Cancer Inst (1978) 0.79
Hyperplastic growth in skin grafts of rabbits. J Hered (1982) 0.79
Characterization of human soft tissue sarcomas in nude mice. Evidence for histogenic properties of malignant fibrous histiocytomas. Am J Pathol (1988) 0.78
Increased oncogenic effect of a low dose of methylcholanthrene in immunodepressed mice. Tumori (1972) 0.78
Evidence for immune facilitation of breast cancer growth and for the immune promotion of oncogenesis in breast cancer. Medicina (B Aires) (1996) 0.77
Tumor susceptibility in two mouse strains with varying doses of carcinogen. Proc Soc Exp Biol Med (1982) 0.76
Infection may have shaped the evolution of the biphasic immune response to cancer. Folia Biol (Praha) (1997) 0.76
DMBA induced papillomas in congenitally athymic (nude) and hereditarily asplenic (Dh/+) mice: contrasts and comparisons with immunologically intact littermates. Dev Comp Immunol (1978) 0.76
The immune basis of dosage-induced reversal of the rank-order of strain susceptibility to MCA. Int J Cancer (1987) 0.76
Rank order of sarcoma susceptibility among mouse strains reverses with low concentrations of carcinogen. Science (1979) 0.76
Cancer immunotherapy by immunosuppression. Theor Biol Med Model (2010) 0.82